Effect of Metoprolol Succinate Sustained-release Tablets Combined with Tirofiban on Cardiovascular Adverse Events in Elderly Patients with AMI After PCI
Objective To observe the effect of metoprolol succinate sustained-release tablets+tirofiban on cardiovascular adverse events in elderly patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods A total of 78 elderly patients with AMI who underwent PCI in our hospital from October 2022 to October 2023 were selected as the research objects. They were divided into control group ( n=39) and observation group (n=39) by random number table method. The control group was treated with aspirin enteric-coated tablets+atorvastatin calcium tablets,and the observation group was treated with metoprolol succinate sustained-release tablets+tirofiban on the basis of the control group. The cardiac function indexes[left ventricular ejection fraction (LVEF),left ventricular end-systolic volume (LVESV),left ventricular end-diastolic volume (LVEDV)],incidence of cardiovascular adverse events (arrhythmia,myocardial re-infarction,severe heart failure,death),quality of life level (SF-36),platelet count,platelet aggregation rate and incidence of adverse reactions were compared between the two groups. Results LVEF in the two groups was higher than that before treatment,LVESV and LVEDV were lower than those before treatment,and LVEF in the observation group was higher than that in the control group,LVESV and LVEDV were lower than those in the control group (P<0.05). The incidence of cardiovascular adverse events in the observation group (10.26％) was lower than that in the control group (20.51％) (P<0.05). The SF-36 score of the two groups was higher than that before treatment,and that of the observation group was higher than that of the control group (P<0.05). The platelet count and platelet aggregation rate of the two groups were lower than those before treatment,and those of the observation group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Metoprolol succinate sustained-release tablets+tirofiban has a positive effect on cardiovascular adverse events after PCI in elderly patients with AMI. It can prevent complications,reduce platelet count and aggregation,improve cardiac function indicators,and improve postoperative quality of life of patients without significant adverse reactions,which is worthy of clinical application.
万方数据
维普
